Advanced Hormone Testing for Women: The Dutch Test, Salivary Hormones, and the Complete Perimenopause Panel

Why Standard Hormone Testing Fails Most Women

A woman experiencing fatigue, irregular cycles, mood changes, sleep disruption, weight gain, or brain fog is often told her hormones are “normal” after a single serum estradiol and FSH measurement. But female hormonal physiology is cyclical, dynamic, and exquisitely sensitive to the interplay between estrogen, progesterone, testosterone, cortisol, thyroid hormones, and insulin. A single blood draw captures one moment in a continuously shifting system — and standard reference ranges are so broad that significant dysfunction can exist entirely within them.

Advanced female hormone testing goes far beyond a serum estradiol level. It maps the full hormonal cycle, assesses estrogen metabolism pathways, evaluates adrenal and thyroid function, and identifies the specific hormonal imbalances driving symptoms. This guide covers every component of a comprehensive female hormonal evaluation — from the Dutch test to salivary cortisol to the complete perimenopause panel — with optimal ranges and clinical interpretation.

Understanding the Female Hormonal Cycle

The menstrual cycle is divided into the follicular phase (days 1 to 14, from menstruation to ovulation) and the luteal phase (days 15 to 28, from ovulation to menstruation). Estradiol peaks just before ovulation; progesterone peaks in the mid-luteal phase (days 19 to 22). Testing at the wrong phase of the cycle produces meaningless results. Progesterone tested in the follicular phase will always be low — that is normal. Estradiol tested at the wrong time misses the ovulatory peak. Timing is everything in female hormone testing.

Estrogen: Estradiol, Estrone, and Estriol

Estradiol (E2)

Estradiol is the primary and most potent estrogen in premenopausal women, produced primarily by the ovarian follicles. Optimal estradiol varies dramatically by cycle phase: follicular phase 30 to 150 pg/mL, ovulatory peak 150 to 500 pg/mL, luteal phase 50 to 200 pg/mL, postmenopause below 30 pg/mL (without HRT). Estradiol drives the development of the uterine lining, supports bone density, cardiovascular health, cognitive function, skin integrity, and mood. Declining estradiol in perimenopause produces the characteristic symptoms of hot flashes, night sweats, vaginal dryness, sleep disruption, and cognitive changes.

Estrone (E1)

Estrone is the primary estrogen in postmenopausal women, produced through peripheral conversion of androstenedione in adipose tissue. Elevated estrone relative to estradiol in premenopausal women can indicate excess adipose tissue or adrenal dysfunction. Optimal estrone in premenopausal women: 17 to 200 pg/mL depending on cycle phase.

Estriol (E3)

Estriol is the weakest of the three estrogens and is produced primarily during pregnancy. In non-pregnant women, estriol is a minor estrogen but is included in some comprehensive hormone panels and is the primary estrogen used in bioidentical vaginal preparations for genitourinary syndrome of menopause.

Estrogen Metabolism: The Critical Missing Piece

How the body metabolizes estrogen is as important as how much estrogen is produced. Estradiol is metabolized in the liver through three primary pathways, producing metabolites with very different biological activities. The 2-hydroxyestrone (2-OH) pathway produces a weak, protective metabolite associated with reduced cancer risk. The 16-alpha-hydroxyestrone (16-OH) pathway produces a potent, proliferative metabolite associated with increased breast and uterine cancer risk. The 4-hydroxyestrone (4-OH) pathway produces a genotoxic metabolite that can damage DNA directly.

The 2:16 ratio — the ratio of 2-OH to 16-OH estrone — is a clinically useful marker of estrogen metabolism quality. Optimal 2:16 ratio: above 2.0. A low 2:16 ratio indicates preferential metabolism through the proliferative 16-OH pathway and is associated with increased breast cancer risk. Cruciferous vegetables (broccoli, cauliflower, Brussels sprouts) contain indole-3-carbinol (I3C) and diindolylmethane (DIM), which shift estrogen metabolism toward the protective 2-OH pathway. This is one of the most evidence-based dietary interventions for estrogen-related cancer risk reduction.[1]

Estrogen metabolite testing requires urine — it cannot be assessed from serum. The Dutch test (described below) is the most comprehensive way to assess estrogen metabolism.

The Dutch Test: The Gold Standard for Female Hormone Assessment

The Dutch test (Dried Urine Test for Comprehensive Hormones), developed by Precision Analytical, is the most comprehensive commercially available hormone test for women. It uses dried urine collected at four time points across a single day to measure sex hormones and their metabolites, adrenal hormones and their metabolites, and the organic acid markers melatonin and 8-OHdG (oxidative stress marker).

What the Dutch Test Measures

The Dutch test measures estradiol, estrone, and estriol; estrogen metabolites (2-OH, 4-OH, 16-OH estrone; 2-methoxy and 4-methoxy estrone); progesterone metabolites (pregnanediol, allopregnanolone); testosterone and its metabolites (androsterone, etiocholanolone, 5a-DHT); DHEA and its metabolites; cortisol and cortisone (free and metabolized); melatonin; and 8-OHdG. This comprehensive metabolite profile reveals not just hormone levels but how hormones are being produced, converted, and cleared — information that serum testing cannot provide.

When to Use the Dutch Test

The Dutch test is most valuable for women with unexplained hormonal symptoms (PMS, PMDD, irregular cycles, fatigue, mood changes, weight gain), women considering or already using hormone replacement therapy (to assess absorption and metabolism), women with a personal or family history of hormone-sensitive cancers (to assess estrogen metabolism pathways), and perimenopausal and postmenopausal women seeking a comprehensive hormonal baseline.

Progesterone

Progesterone is produced by the corpus luteum after ovulation and is the dominant hormone of the luteal phase. It balances estrogen’s proliferative effects, supports sleep (through conversion to allopregnanolone, a GABA-A receptor modulator), reduces anxiety, and is essential for maintaining early pregnancy. Optimal mid-luteal serum progesterone (day 19 to 22 of a 28-day cycle): above 10 ng/mL; ideally 15 to 25 ng/mL. Values below 7 ng/mL indicate inadequate luteal phase progesterone — a common and frequently missed cause of PMS, PMDD, anxiety, sleep disruption, and infertility.

Progesterone declines before estradiol in perimenopause, producing a period of relative estrogen dominance characterized by heavy periods, breast tenderness, mood changes, and sleep disruption — often years before hot flashes begin. Identifying this early progesterone decline is one of the most clinically valuable applications of comprehensive female hormone testing.

Testosterone in Women

Testosterone is essential for female libido, energy, muscle mass, bone density, cognitive function, and mood. Women produce testosterone in the ovaries and adrenal glands at approximately 5 to 10% of male levels. Optimal total testosterone for women: 30 to 70 ng/dL. Optimal free testosterone: 1 to 8.5 pg/mL. Low testosterone in women — which is common after menopause, oophorectomy, and with oral contraceptive use (which raises SHBG and suppresses ovarian androgen production) — causes low libido, fatigue, reduced muscle mass, depression, and cognitive decline. Elevated testosterone in women suggests PCOS, adrenal hyperplasia, or insulin resistance.

FSH and LH: Markers of Ovarian Reserve and Cycle Status

FSH (follicle-stimulating hormone) rises as ovarian reserve declines — the pituitary works harder to stimulate aging follicles. Optimal day 3 FSH (early follicular phase): below 10 IU/L. FSH above 10 IU/L suggests diminished ovarian reserve; above 25 IU/L indicates perimenopause; above 40 IU/L is consistent with menopause. LH surges at ovulation and can be used to confirm ovulation timing. The LH:FSH ratio is elevated in PCOS (typically above 2:1 or 3:1). Anti-Müllerian hormone (AMH) is a more sensitive and cycle-independent marker of ovarian reserve — optimal for women under 35: above 2.0 ng/mL; declining with age to below 1.0 ng/mL in late perimenopause.

The Perimenopause Panel

Perimenopause — the transition to menopause — typically begins in the mid-40s and lasts 4 to 10 years. It is characterized by irregular cycles, fluctuating and eventually declining estradiol, declining progesterone, rising FSH, and a constellation of symptoms including hot flashes, night sweats, sleep disruption, mood changes, cognitive changes, vaginal dryness, and joint pain. A comprehensive perimenopause panel includes estradiol (day 3 and mid-luteal), FSH (day 3), LH, AMH, progesterone (mid-luteal), testosterone (total and free), SHBG, DHEA-S, AM cortisol, full thyroid panel, fasting insulin, HbA1c, and lipid panel (cardiovascular risk rises significantly after menopause).

Salivary Hormone Testing

Salivary hormone testing measures the free (bioavailable) fraction of steroid hormones — the fraction that has crossed from blood into saliva through passive diffusion. Because only free hormones cross into saliva, salivary testing reflects tissue-available hormone levels rather than total circulating levels. Salivary testing is particularly useful for cortisol (the 4-point salivary cortisol test is the gold standard for assessing the diurnal cortisol rhythm), progesterone (salivary progesterone correlates well with tissue levels and is useful for monitoring topical progesterone absorption), and estradiol (useful for monitoring transdermal estradiol absorption, where serum levels may not accurately reflect tissue delivery).

Salivary testing has limitations: it is more susceptible to contamination, requires careful collection protocols, and reference ranges are less standardized than serum. It is best used as a complement to serum and urine testing rather than a replacement.

Adrenal Hormones: DHEA-S and Cortisol

The adrenal glands produce DHEA-S, cortisol, and a significant proportion of female androgens. Optimal DHEA-S for women under 50: 150 to 300 µg/dL; declining with age. Low DHEA-S is associated with fatigue, low libido, depression, immune dysfunction, and accelerated aging. Chronically elevated cortisol — from psychological stress, poor sleep, or HPA axis dysregulation — suppresses ovarian function, impairs thyroid conversion, drives insulin resistance, and accelerates the hormonal changes of perimenopause. The 4-point salivary cortisol test (morning, noon, afternoon, evening) is the most clinically informative assessment of adrenal function and HPA axis rhythm.

Thyroid Hormones and Female Hormonal Health

Thyroid dysfunction is significantly more common in women than men and profoundly affects female hormonal health. Hypothyroidism raises SHBG (reducing free testosterone and estradiol availability), impairs progesterone production, causes irregular cycles, and produces symptoms that overlap extensively with perimenopause and hormonal imbalance. Hashimoto’s thyroiditis — the most common autoimmune disease in women — can be present for years before TSH becomes abnormal. A full thyroid panel including TSH, Free T3, Free T4, Reverse T3, and thyroid antibodies (TPO and thyroglobulin) is essential in any comprehensive female hormonal evaluation. See our companion guide: Beyond the Basic Panel: The Complete Guide to Advanced Blood Work and Lab Testing.

Insulin and Metabolic Hormones

Insulin resistance is the hormonal driver of PCOS — the most common endocrine disorder in women of reproductive age, affecting 8 to 13% of women globally. Hyperinsulinemia stimulates ovarian androgen production, suppresses SHBG, and disrupts the LH:FSH ratio, producing the characteristic features of PCOS: irregular cycles, elevated androgens, and polycystic ovaries. Even in women without PCOS, insulin resistance drives estrogen dominance (through increased aromatization in adipose tissue), suppresses progesterone production, and accelerates the hormonal changes of perimenopause. Fasting insulin, HbA1c, and the triglyceride:HDL ratio are essential components of any comprehensive female hormonal evaluation.

A Practical Testing Strategy

Premenopausal women with symptoms: Day 3 serum panel (FSH, LH, estradiol, testosterone, SHBG, DHEA-S, prolactin, thyroid panel, fasting insulin) plus mid-luteal progesterone (day 19 to 22). Dutch test for comprehensive metabolite assessment if symptoms persist or estrogen metabolism assessment is needed.

Perimenopausal women: Full perimenopause panel as described above, plus Dutch test, 4-point salivary cortisol, and cardiovascular risk markers (ApoB, Lp(a), hs-CRP).

Postmenopausal women: Estradiol, estrone, FSH, testosterone (total and free), SHBG, DHEA-S, AM cortisol, full thyroid panel, fasting insulin, HbA1c, full cardiovascular panel, bone density (DEXA). Dutch test if on HRT to assess absorption and metabolism.

Women on oral contraceptives: Standard serum testing is unreliable while on OCP (suppressed HPG axis). Dutch test can assess adrenal function and estrogen metabolism. Consider testing 3 months after discontinuation for a true hormonal baseline.

For a comprehensive framework integrating hormonal testing with advanced longevity diagnostics, see: Longevity Diagnostics: The Advanced Screening Tools That Go Beyond Standard Medicine.

Related Reading

• Beyond the Basic Panel: The Complete Guide to Advanced Blood Work and Lab Testing
• Longevity Diagnostics: The Advanced Screening Tools That Go Beyond Standard Medicine
• Advanced Hormone Testing for Men: Beyond Testosterone
• Heart Rate Variability (HRV): The Nervous System Metric That Predicts Everything

References

1. Bradlow HL, et al. 2-Hydroxyestrone: The “good” Estrogen. Journal of Endocrinology. 1996;150(Suppl):S259-S265.
2. Stanczyk FZ, et al. Standardization of Steroid Hormone Assays. Cancer Epidemiology, Biomarkers and Prevention. 2007;16(9):1713-1719.
3. Prior JC. Progesterone for Symptomatic Perimenopause Treatment. Journal of Obstetrics and Gynaecology Canada. 2011;33(12):1255-1263.
4. Davis SR, et al. Testosterone for Women: The Clinical Investigators. Lancet Diabetes and Endocrinology. 2015;3(12):980-992.
5. Teede HJ, et al. Recommendations from the International Evidence-Based Guideline for the Assessment and Management of PCOS. Human Reproduction. 2018;33(9):1602-1618.
6. Santoro N, et al. Menopausal Symptoms and Their Management. Endocrinology and Metabolism Clinics of North America. 2015;44(3):497-515.
7. Shifren JL, Gass ML. The North American Menopause Society Recommendations for Clinical Care of Midlife Women. Menopause. 2014;21(10):1038-1062.